Accession Number:

ADA620823

Title:

Antibiofilm and Antimicrobial Efficacy of DispersinB (registered trademark)-KSL-W Peptide-Based Wound Gel Against Chronic Wound Infection Associated Bacteria

Descriptive Note:

Journal article

Corporate Author:

ARMY INST OF SURGICAL RESEARCH FORT SAM HOUSTON TX

Report Date:

2014-01-21

Pagination or Media Count:

9.0

Abstract:

The medical importance of bacterial biofilms has increased with the recognition of biofilms as one of the major contributors to the slow or non-healing chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Being a protected community of microorganisms, biofilms are notoriously refractory to antibiotic treatments. As the conventional treatment modalities have proven ineffective, this study provides the in vitro evidence to support the use of a novel combination of DispersinB antibiofilm enzyme that inhibits biofilm formation and disperses preformed biofilm, and thus making the biofilm bacteria more susceptible to a broad-spectrum KSL-W antimicrobial peptide. The combination of Silver-SeptTM, DispersinBregistered trademark and KSL-Wregistered trademark peptide showed synergistic antibiofilm and antimicrobial activity against chronic wound infection associated biofilm-embedded bacteria such as Methicillin- resistant Staphylococcus aureus MRSA ,Staphylococcus epidermidis, Coagulase-negative Staphylococci CoNS, and Acinetobacter baumannii. In addition, the wound gel formulation comprising DispersinB, KSL-W peptide based-wound gel was significantly more effective in inhibiting the bio- film-embedded MRSA , S. epidermidis, CoNS, Vancomycin-resistant Enterococci, A. baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa P less than 0.05. Thus, this study provides promising evidence for the potential application of antibiofilm-antimicrobial DispersinBregistered trademark -KSL-W wound gel in chronic wound management.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research
  • Microbiology
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE